May 21, 2020

PD-L1 Expression on Tumour-Infiltrating Immune Cells Has No Prognostic Value in Renal Cell Carcinoma

By Eric Ramos

CHICAGO -- May 21, 2020 -- Programmed death ligand 1 (PD-L1) status on tumour-infiltrating immune cells was not an independent prognostic factor for patients with recurrent or metastatic renal cell carcinoma, according to a study presented at the 2020 American Urological Association (AUA) Virtual Meeting.

However, positive PD-L1 status was associated with poor prognostic factors, reported Katsunori Tatsugami, MD, Kyushu University, Fukuoka, Japan.

The researchers examined 770 surgical specimens from patients with recurrent or metastatic renal cancer, of which 770 of which 315 were PD-L1-positive.

PD-L1-positive status was more common in patients with higher clinical stage, higher Fuhrman grade, and presence of sarcomatoid component.

A higher proportion of PD-L1-positive patients had poor prognostic features at the start of first-line therapy. Of the patients with poor Memorial Sloan Kettering Cancer Center (MSKCC) risk, 17.5% were PD-L1-positive compared with 7.3% of patients without PD-L1 expression. Of the patients with poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, 29.2% had positive PD-L1 status compared with 14.9% of patients with negative status.

In line with this, fewer PD-L1-positive patients had good prognostic features at the start of first-line therapy. Only 11.4% of patients with positive PD-L1 status had favourable MSKCC risk compared with 29.7% of patients with negative status. Favourable IMDC risk was 10.8% and 26.2%, respectively.

The median overall survival in PD-L1-positive patients was 30.9 months compared with 37.5 months in PD-L1-negative patients.

The findings suggest that PD-L1 expression may be used as a complementary prognostic factor in the management of patients with renal cell carcinoma.

Funding for this study was provided by Chugai Pharmaceutical.

[Presentation title: Prognostic Value of PD-L1 Expression on Tumor-Infiltrating Immune Cells in Renal Cell Carcinoma (ARCHERY Study) Abstract LBA02-02]
Log in to post comments

Tell us what you think of DG News

Click to like Click to dislike